Dermaglow is building a way to predict eczema (atopic dermatitis) flares before they appear
Dermaglow is building a way to predict eczema (atopic dermatitis) flares before they appear. Families managing eczema moisturize every day, and flares still arrive without warning. By the time a flare is visible, the skin is already broken down and the child is already hurting. We want to give patients and parents an early warning, so they can start the treatment their dermatologist already prescribed sooner, before a flare takes hold. Where we are We're starting by validating the science. Published research suggests that skin measurements, specifically transepidermal water loss (TEWL) and skin pH, change in the days before a flare. We're designing a clinical study with commercial instruments to test whether this signal can be used to predict when a flare is about to emerge. Only then will we build our own device. Who we are Dermaglow was founded by David Chuquillanqui (Co-founder, CEO), who has had eczema since childhood, and Rohith Bandi (Co-founder, CTO), who leads hardware and firmware; both are biomedical engineers from Drexel University. Also, we are part of the Nucleate Activator 2026-27. We'd love to hear from dermatologists and clinical researchers, early-stage medtech investors, and families living with eczema.